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Abstract 
Pulmonary arterial hypertension (PAH) is multifactorial disadptive disease with poor clinical outcomes associated 
with increased pulmonary artery pressure resulting in primary small-to-moderate pulmonary artery remodeling. 
Numerous factors, including smooth muscle cell proliferation, vasospasm, vascular fibrosis and occlusion, direct 
vascular injury and inflammation, impaired repair of vasculature, are involved in the pathogenesis of PAH. It has 
been suggested that galectin-3 as a biomarker of excessive fibrosis and inflammation can be useful predictor of 
both severity and prognosis in patient with PAH. The short communication is reported that elevated Gal-3 levels 
were found in majority patients with PAH depending on clinical status and of the disease. Although elevated Gal-
3 levels were associated with a higher risk of all-cause mortality, cardiovascular mortality, and right ventricle heart 
failure, the value of this biomarker in PAH patients at high risk stratification is uncertain and requires to be 
investigated in large clinical trials. 
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1. Introduction 
Pulmonary arterial hypertension (PAH) is a steadily progressive maladaptive disease with potentially fatal 
consequences that has been demonstrated increasing prevalence worldwide (Lai, Y.C. et al., 2014). Nature 
evolution of PAH closely related to vascular remodeling and endothelial dysfunction that lead to obstruction of 
small-to-moderate pulmonary arteries, resulting in increased pulmonary artery pressures and pulmonary vascular 
resistance associated with uncoupling oxygen supply and blood saturation, hypoxia, right ventricle heart failure 
and multi organ insufficiency (Galiè N. et al., 2015; Hoeper ,M. M. et al., 2013). There were found numerous 
factors, which contributed to several faces of the PAH including smooth muscle cell proliferation, vasospasm, 
vascular fibrosis and occlusion, direct vascular injury and inflammation, impaired repair of vasculature (Yu, J. et 
al., 2013). All these factors corresponding to imbalance of vasodilators (nitric oxide - NO, and prostacyclin) and 
vasoconstrictors (endothelin-1 - ET-1, thromboxane A2) are crucial for clinical presentation, severity and prognosis 
of the disease (Sobolewski, A., et al., 2008). In fact, dysregulation these factors via increased oxidase (NADPH 
oxidase family, xanthine and aldehyde oxidases) activity and bone morphogenetic protein receptor-2 signaling 
mechanism produce reactive oxygen species (superoxide, hydrogen peroxide, peroxynitrite) that disrupt canonic 
NO synthase pathway, lead to mitochondrial dysfunction and inflammation, potentiate proliferative response of 
the vasculature cells, mediate thickness and fibrosis of pulmonary artery vasculature (Bowers, R. et al., 2004; 
Bryant AJ. et al., 2016). In this context, excessive inflammation and fibrosis are core players in pathogenesis of 
PAH corresponding to severity and prognosis of the disease, and biomarkers reflecting both faces of pathogenesis 
of PAH, such as galectin-3, could be predict nature evolution of the disease and prognosticate a risk of poor clinical 
outcomes. The aim of the short communication is to summarize knowledge regarding the role of galectin-3 in risk 
stratification of PAH patients.  
2. Galectin-3: Biological Role in PAH 
Galectin-3 (Gal-3) is beta-galactoside binding lectin that is synthesized and secreted by inflammatory cytokine-
activated macrophages / mononuclears (Vasta G. R., 2012). Gal-3 was found a useful biomarker with high 
predictive importance in heart failure risk stratification (Gehlken, C. et al., 2018). Previous studies have shown 
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that Gal-3 was up-regulated in adventitia of pulmonary arteries of hypoxia-induced PAH and it regulated the 
proliferation, differentiation, and accumulation of extracellular matrix by synthesis of collagen and other fibrotic 
components (Luo, H. et al., 2017). Gal-3 exhibited pro-fibrotic effects interacting of platelet-derived growth factor 
(Guo, S., & Feng, Z., 2015), transforming growth factor-beta-1 (TGF-β1), matrix metalloproteinase-9 (MMP-9) 
(Wang, X. et al., 2017) and NADPH oxidase 4 (He, J. et al., 2017a). Interestingly, TGF-β1 was able to promote 
the expression of Gal-3 and its translocation, while blockage of STAT3 suppressed the expression of Gal-3 induced 
by TGF-β1 (He, J. et al., 2017a). Thus, TGF-β1-dependent vascular fibrosis is mediated by Gal-3 / MMP-9 / 
STAT3 signaling cascade. Additionally, an inhibition of Gal-3 led to reduced hypoxia-induced inflammatory 
response in human pulmonary arterial endothelial cells and human pulmonary arterial smooth muscle cells (He, J. 
et al., 2017b). This effect associated with suppressed realizing of tumor necrosis factor-alpha and interleukin-1, 
reduced expression of intercellular adhesion molecule-1 and switching phenotype of human pulmonary arterial 
smooth muscle cells from a “contractile” to a “synthetic” (Hao, M., Li, M., & Li, W., 2017). Therefore, Gal-3 
markedly triggers proliferation and differentiation of smooth muscle cells of vasculature in tandem with 
aldosterone increasing expression of vascular cell adhesion molecule 1 (VCAM-1) and interleukin-12: a cytokine 
with pro-inflammatory and anti-angiogenic activity (Calvier, L. et al., 2016). There is evidence that both Gal-3 
and aldosterone failed functional capabilities of resident cells including endothelial progenitor cells, which are a 
component of endogenous vascular repair system (Berezin, A.E., 2017). Moreover, number of circulating EPCs 
with pro-angiogenic phenotypes inversely associated with Gal-3 levels and predicts endothelial dysfunction 
(Berezin, A.E., 2016). 
3. Galectin-3 as a Prognosticator in PAH 
There was significant correlation between Gal-3 levels in PAH individuals with mean pulmonary artery pressure 
and right ventricular dysfunction, but this association persisted after adjustment for CV risk factors and severity 
of inflammation (Fenster, B.E.m et al., 2016). Although elevated Gal-3 levels were associated with a higher risk 
of all-cause mortality, CV mortality, and heart failure (Mazurek, J.A., et al., 2017), the role of Gal-3 in PAH 
patients at high risk stratification is uncertain. Indeed, authors reported that Gal-3 was a strong predictor of 
mortality after adjusting for age, sex, race, glomerular filtration rate, NT-proBNP, medications, and aetiology of 
PAH (Mazurek, J.A., et al., 2017). However, Gal-3 associates with severity of vascular remodeling in PAH and 
act as a critical regulator in the pathogenesis of PAH (Barman, S. A., 2018). Finally, Gal-3 may add prognostic 
value beyond traditional CV risk factors and it could be possible therapeutic target for individuals with PAH 
(Berezin, A. E., 2016). 
In conclusion, elevated Gal-3 levels were found in majority patients with PAH depending on clinical status and of 
the disease. Estimating of prognosis, risk stratification and choosing of the most effective therapy in PAH might 
correspond to serial measures of Gal-3. In addition to conventional findings including NYHA functional class, 
hemodynamic features and risk scoring based on clinical criteria, the analysis of Gal-3 in peripheral blood can be 
useful to evaluate disease severity and medical care responses. 
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